What is worthy of note is also the mention about seasonality. They saw increased sales of Daybue in December from patients ordering before holiday season. This resulted in some drop off in January but in February sales again returned to pre holiday sales. Clearly Acadia is very comfortable with recent February data. In fact they are continuing to open new markets in Europe H1 25 with an MAA application. This will then allow launch in Europe! Probably not included in any meaningful way in 25 guidance at this stage. Early adoption will allow Acadia to exceed guidance for 25 - smart move!!
Acadia, page-255
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.71 |
Change
-0.590(3.41%) |
Mkt cap ! $2.135B | |||
| Open | High | Low | Value | Volume |
| $17.50 | $17.55 | $16.57 | $10.01M | 594.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 598 | $16.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.87 | 1676 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |